The papillary renal cell carcinoma-associated t(X;1)(p11;q21) leads to fusion of the transcription factor TFE3 gene on the X-chromosome to a novel gene, PRCC, on chromosome 1. As a result, two putative fusion proteins are formed: PRCCTFE3, which contains all known domains for DNA binding, dimerization, and transactivation of the TFE3 protein, and the reciprocal product TFE3PRCC. Upon transfection into COS cells, both wild type and fusion proteins were found to be located in the nucleus. When comparing the transactivating capacities of these (fusion) proteins, signi®cant dierences were noted. PRCCTFE3 acted as a threefold better transactivator than wild type TFE3 both in a TFE3-speci®c and in a general (Zebra) reporter assay. In addition, PRCC and the two fusion proteins were found to be potent transactivators in the Zebra reporter assay. We propose that, as a result of the (X;1) translocation, fusion of the N-terminal PRCC sequences to TFE3 alters the transactivation capacity of the transcription factor thus leading to aberrant gene regulation and, ultimately, tumor formation. Oncogene (2000) 19, 69 ± 74.
Introduction
Based on their histologic appearance, renal cell cancers can be divided into several groups. Chromophilic tumors which mostly show a papillary growth pattern, and are thus commonly referred to as papillary renal cell cancers, constitute 10 ± 15% of the cases. Within this group, a subset is encountered with chromosomal translocations involving the Xp11region, mostly a (X;1)(p11;q21) translocation. There is accumulating evidence that these tumors de®ne a distinct subgroup of renal cell cancers with a relatively early age of onset and a lower male-female preponderance as compared to other renal cell cancers (Tonk et al., 1995; Dijkhuizen et al., 1998) .
In two cases, the (X;1)(p11;q21) translocation has been reported as the sole cytogenetic abnormality present (Meloni et al., 1993; de Jong et al., 1986) , indicating that the genes involved may play a pivotal role in tumorigenesis. Positional cloning of a genomic breakpoint fragment revealed that as a result of the translocation the transcription factor TFE3 gene on the X-chromosome is fused to a novel gene, PRCC, on chromosome 1 (Weterman et al., 1996a,b; Sidhar et al., 1996) . As a consequence, two reciprocal fusion genes, TFE3PRCC and PRCCTFE3, are formed encoding two putative fusion proteins. TFE3 is a ubiquitously expressed transcription factor that was originally identi®ed as a protein binding to the mE3 element of the immunoglobulin heavy chain enhancer (Beckmann et al., 1990) which is thought to be crucial for the activation of immunoglobulin heavy chain genes (Banerji et al., 1983; Gillies et al., 1983; Neuberger 1983) . The TFE3 protein belongs to a superfamily of transcription factors, all of which contain a basic helix ± loop ± helix region followed by a leucine zipper (bHLHzip). Both domains are essential for DNA binding and dimerization (Beckmann and Kadesch, 1991; Roman et al., 1992) . The PRCCTFE3 fusion protein still contains these domains, in addition to the N-terminal 156 amino acids of PRCC. The reciprocal translocation product, TFE3PRCC, contains the Nterminal 178 amino acids of TFE3 harboring none of the known functional domains of TFE3, and the Cterminal 335 amino acids of PRCC.
The PRCC gene exhibits no signi®cant homologies to other known genes. It is also ubiquitously expressed and its predicted protein shows a relatively high content of prolines and glycines. Within the Nterminal translocated part, the relative content of prolines is 27%. PRCC contains three P-X-X-P motifs which have been encountered in proteins that interact with SH3 domains of other proteins (Sudol, 1998; Ren et al., 1993) . Together with the presence of several potential sites for kinase phosphorylation, among which one for tyrosine phosphorylation, it may be speculated that PRCC is involved in cellular signaling. Homopolymeric stretches of prolines and glycines have also been encountered in transactivation domains (Gerber et al., 1994) , thus pointing at a role in transcription regulation. Indeed, the amino-acid composition of the N-terminal part of PRCC is remarkably similar to that of other known transactivation domains such as the one in Hox4.2 (Artandi et al., 1995) .
Tumor-speci®c chromosomal translocations frequently lead to the fusion of genes encoding transcription factors (Rabbitts, 1994) . For example, in t(11;22)-positive Ewing sarcomas the transactivation domain of EWS is fused to the DNA-binding domain of FLI1, a member of the Ets family of transcription factors (Delattre et al., 1992) . Such fusions may lead to inappropriate expression of target genes (Sorensen and Triche, 1996) . In addition, it has been demonstrated that expression of EWS/FLI1 leads to transcription of at least a partially distinct set of genes, as compared to cells expressing wild type FLI1 (Braun et al., 1995) . Alternatively, the subcellular localization of the fusion protein may be altered in such a way that it interferes with the ability of the transcription factor to exert its normal function. For example, in t(1;11)-positive acute leukemias, a fusion between the cytoplasmic protein eps15 and the transcription factor MLL/HRX/ALL1 is observed. The HRXeps15 fusion protein is also located in the nucleus, but in distinct nuclear subdomains (Rogaia et al., 1997) .
Therefore, we sought to establish the subcellular localization of TFE3, PRCC, and the respective fusion proteins PRCCTFE3 and TFE3PRCC. In addition, we have determined the transactivational properties of these (fusion) proteins using general (Zebra) and TFE3-speci®c reporter systems.
Results

Nuclear localization of the TFE3 and PRCC (fusion) proteins
For direct visualization of the cellular location of TFE3, PRCC and the derived fusion proteins, the corresponding cDNAs were cloned in frame with green uorescent protein (GFP) in the mammalian expression vector pEGFP-C, followed by transient transfection into green monkey kidney epithelial cells (COS). Both living cells and ®xed cells were analysed. DAPI staining was performed for identi®cation of the position of the nucleus.
Typical patterns are shown in Figure 1 . In the majority of cells, normal TFE3 was found to be located in the nucleus, as might be expected for a transcription factor. However, in a minority of cells cytoplasmic¯uorescence was also observed. In a few cases, the nucleus even appeared to be void of uorescence ( Figure 1a) . The patterns within the nucleus varied from relatively small dots dispersed throughout the nucleus, except for a few negative areas which may correspond to the nucleoli (Figure 1c ), to irregular patches ( Figure 1a) . Plating of the cells at dierent levels of con¯uency before electroporation did not aect the variability in the patterns observed. Likewise, variation in culturing period between transfection and harvesting did not have any eect on the ratio of these patterns. When comparing these localization patterns to those of the TFE3 and PRCC derived fusion proteins, no apparent dierences could be detected. PRCCTFE3 localization was nuclear in the majority of cells ( Figure  1i , j,k), but cytoplasmic¯uorescence was also observed in a minority of the cells. Likewise, PRCC and TFE3PRCC showed similar nuclear patterns ( Figure  1g ,h). No apparent dierences were observed between living cells and cells ®xed with formaldehyde. Expression of all transfected proteins was optimal between 24 ± 48 h after transfection. Despite the variation in patterns, no obvious dierences were noted in expression levels or stability when comparing the¯uorescence of wild type and fusion proteins.
Transactivation by TFE3 and PRCCTFE3 using a mE3-luciferase reporter To determine whether the transactivating capacity of TFE3 is altered as a result of the fusion to PRCC, we made use of a luciferase reporter construct in which mE3 elements are coupled to a minimal promoter (TATA) and a luciferase reporter gene (Figure 2 ). The DNA binding and dimerization domains present in the TFE3 and PRCCTFE3 proteins will enable binding to this reporter construct. Expression constructs were transfected in ®vefold excess to ensure maximum binding to the reporter construct. If transactivation domains are present, the luciferase gene will be activated. Since the TFE3 cDNA we recently described (Weterman et al., 1996a) is longer than the mouse cDNA reported previously (TFE3-L) (Roman et al., 1991) we decided to include this latter construct for reference. A mutant form of TFE3 (TFE3-S) which lacks one of the two known transactivation domains and is known to cause a threefold decrease in transactivation upon comparison to TFE3-L (Roman et al., 1991) was also included. In addition, the reciprocal fusion protein TFE3PRCC and wild type Transactivation is expressed relative to that of the control/empty vector pZd1, re¯ecting the basal activity of the minimal promoter. (b) Western blot analysis of the pellet fraction of the COS cell lysates which were also used for the reporter assays. The pZd1 vector (pZd) and Zd-fusions of the respective proteins (TFE3PRCC, PRCCTFE3, PRCC, TFE3) were analysed. The size of the Zd-TFE3 and Zd-PRCCTFE3 proteins is indicated by an arrow PRCC were tested, although they both lack the domains needed for DNA-binding and dimerization. As expected, no transactivation above background was observed for these proteins (results not shown).
As can be seen in Figure 3 , activation resulting from transfection of TFE3-S is 2 ± 3-fold lower than that of the longer products TFE3-L and full length TFE3. No signi®cant dierences were observed between the latter two proteins. However, the activation caused by PRCCTFE3 was signi®cantly elevated (threefold) compared to that caused by the normal TFE3 protein.
Transactivation by TFE3 and PRCC (fusion) proteins using the Zebra-luciferase reporter
Since the PRCCTFE3 fusion protein showed increased transactivation as compared to TFE3 in the TFE3-speci®c reporter assay, we examined the transactivating capacities of wild type PRCC and the corresponding fusion protein TFE3PRCC, next to wild type TFE3 and PRCCTFE3, using a general transactivation system (Zebra). All wild type and fusion proteins were cloned into a pZd vector as depicted in Figure 2 . Zd codes for a mutant Zebra protein which contains dimerization and DNA-binding domains but lacks the transactivation domain. As a reporter, a construct was used containing Zebra-responsive elements upstream of a minimal promoter coupled to the luciferase gene. In this system, both PRCC and the fusion proteins TFE3PRCC and PRCCTFE3 turned out to be more potent transactivators than TFE3 (2 ± 6-fold; Figure 4a ). The increase in transactivating capacity of PRCCTFE3 as compared to TFE3 was similar to that observed in the mE3 reporter system (threefold). As a control, Western blot analysis was performed demonstrating that equal amounts of TFE3 and PRCCTFE3 proteins were present in the lysates (Figure 4b ).
Discussion
Exogeneously expressed TFE3, PRCC and corresponding fusion proteins all exhibited nuclear localization patterns. In each case there was some variation both in intensity and in the extent and size of the positive areas. However, similar patterns and intensities were noted when comparing the wild type and fusion proteins. In the majority of cells, TFE3 is located in the nucleus, as might be expected for a transcription factor. A nuclear localization signal (NLS) has been identi®ed which is also present in other members of the TFE3 family of proteins (TFE3, TFEB, TFEC, and the microphtalmia factor mi). Accordingly, mutations in this sequence led to aberrant localization of the microphtalmia factor mi (Takebayashi et al., 1996) . This NLS is located at the C-terminal side of the fusion junction. Within the PRCC sequence, another NLS could be identi®ed (KPKKRK at position 137) at the N-terminal side of the fusion. Consequently, PRCCTFE3 contains both NLS sequences, whereas the TFE3PRCC fusion protein lacks these NLS. Nevertheless, this protein is still located in the nucleus. When examining the full length sequence of TFE3, a potential alternative NLS (RRERRE) was detected at position 130, N-terminal to the breakpoint. This may explain the observed nuclear localization of TFE3PRCC. On the other hand, it is known that proteins without a consensus NLS may be directed to the nucleus through strong interactions with other nuclear proteins or through the presence of as yet unidenti®ed nuclear localization signals (Weis, 1998) . There was no apparent change in the localization of the fusion proteins as compared to normal TFE3 and PRCC. To con®rm that the¯uorescence was indeed caused by the GFP-fusion constructs, a polyclonal anti-PRCC antiserum was also used which showed the same nuclear localization patterns (not shown). In addition, no apparent dierences were noted upon comparison of the localization patterns in living and formaldehyde ®xed cells, indicating that the patterns observed were genuine and not due to ®xation artefacts.
When comparing the transactivating capacity of TFE3 with that of PRCCTFE3, activation was increased threefold through the addition of N-terminal PRCC sequences. This dierence was observed in both reporter systems used. In addition, it was found that PRCC itself can function as a transactivating protein.
We conclude that the N-terminal fragment of PRCC adds a transactivating domain to the PRCCTFE3 protein, resulting in increased transactivation of the reporter gene. Future experiments will be aimed at delineation of the exact location of the transactivation domain within this region. TFE3-S showed a lower transactivation level (2 ± 3-fold) than either one of the longer proteins (TFE3 and TFE3-L) which is consistent with the results published by Roman et al. (1991) . Since there was no signi®cant dierence in transactivation between TFE3 and TFE3-L, it can be concluded that the extra N-terminal sequences of the full length TFE3 do not contain transactivation domains. In the process of cloning the TFE3 product, we identi®ed a minor alternative transcript present in RT ± PCR products of RNA from both normal and tumor tissues, lacking 65 nt within the coding region. This deletion results in a frameshift causing a premature stop, thus leading to the formation of a short protein of 110 amino acids. This construct was not included in our assays.
The reciprocal product TFE3PRCC which lacks the N-terminal portion of PRCC can still act as a transactivator. Its transactivating capacity does not signi®cantly dier from that of wild type PRCC as measured in the Zebra reporter assays. In this system, TFE3 was a less potent transactivator. It can be concluded that wild type TFE3 and PRCC both contain domains capable of transactivation. However, the most striking eect of the translocation is the elevated transactivation capacity of the PRCCTFE3 fusion product. Recently, two variants of the t(X;1) translocation were reported in which TFE3 is fused to the splicing factor genes PSF and NonO resulting in fusion of almost the entire splicing factor protein to the C-terminal part of TFE3 containing the DNA-binding domain (Clark et al., 1997) . This suggests that indeed the formation of the PRCCTFE3 fusion product is the most critical for tumor formation. The alteration in transactivating capacity may lead to aberrant expression of TFE3 target genes. Alternatively, non-target genes may be activated through interactions of Nterminal PRCC sequences with other nuclear proteins and/or transcription factors. Previously, TFE3 has been reported to interact with other transcription factors (Rao et al., 1997) . In non-lymphoid cells it was shown, using a combination of in vitro and in vivo assays, that a three-protein-DNA complex can be formed on a minimal B-cell-speci®c m enhancer. PU.1, a macrophage-speci®c factor, and Ets, both members of the ETS family of proteins, can bind to the mA and mB sites within this enhancer. Binding of TFE3 to the adjacent mE3 element leads to optimal transactivation of the enhancer (Rao et al., 1997) . Recently, TFE3 and Smad3, an intermediate in TGFb signaling, were shown to synergistically activate the PE2 promoter, an E-box containing fragment of the plasminogen activator inhibitor PAI-1 in mutant HT1080 ®brosarcoma cells. Binding of both these proteins was found to be indispensable for TGFbinducible activation of the PE2 promoter (Hua et al., 1998) . Taken together, TFE3 may function in concert with other more tissue-restricted transcription factors and/or transactivating proteins to drive the expression of target genes. The addition of PRCC sequences to the C-terminal part of TFE3 may lead to novel protein-protein interactions which in turn may interfere with the normal regulation of gene expression, ultimately resulting in tumorigenesis.
Materials and methods
Plasmid constructs
Full length cDNAs for TFE3, PRCC, TFE3PRCC, and PRCCTFE3 were cloned in frame with green¯uorescent protein (GFP) in pEGFP-C vectors for subcellular localization studies, or out of frame to the GFP in pEGFP-N vectors (Clontech, Palo Alto, CA, USA) for transactivation studies. Reporter constructs containing mE3 elements coupled to a luciferase reporter gene were generously provided by Dr Calame (Department Microbiology, Columbia University, NY, USA), as were expression constructs containing the previously described TFE3-L, and TFE3-S cDNAs (Roman et al., 1991) . For use of the Zebra transactivation assay, full length cDNAs encoding TFE3, PRCC, and their respective fusion proteins were cloned in frame to the Zd protein into the pZd vector (Askovic and Baumann, 1997) . For our use, the HindIIIBamHI restriction fragment containing seven Zebra-responsive elements and the minimal E4 promoter of EBV of the described reporter construct was isolated, ®lled in to create blunt ends, and cloned into the SmaI site of the pGL2basic vector (Promega, Madison, WI, USA) which contains the luciferase reporter gene.
Cellular localization assays
Green monkey kidney COS1 and COS7 cells were grown in DMEM with 10% fetal calf serum until subcon¯uent. Approximately 2 ± 5610 7 cells were used per electroporation. Electroporations were performed using a Genepulser and capacitance extender (Biorad, Hercules, CA, USA), in 0.4 cm electroporation cuvettes (Eurogentec, Luik, Belgium) at 0.26 kV, 960 mF. Subsequently, cells were plated onto poly-L-Lysine coated microscope slides, grown for 24 ± 48 h, and washed with phosphate buered saline (PBS) prior to analysis under a Zeiss Axiophot epi¯uorescence microscope equipped with appropriate ®lters. Alternatively, cells were ®xed in 2% acid-free formaldehyde for 30 min at room temperature, washed with PBS, and stained with 0.5 mg/ml of DAPI (Serva, Heidelberg, Germany) for 15 ± 20 min at room temperature, washed twice with PBS-Tween, once with PBS, followed by rinsing in water (26), dehydration in methanol, and mounting in Mowiol (Hoechst, Frankfurt am Main, Germany). Digital images were recorded using Oncor-image software (Gaithersburgh, MD, USA) with a cooled CCD camera (Sensys, Photometrics, Tucson, AZ, USA).
Transactivation assays
COS7 cells were transiently transfected with 2.5 mg of a bGAL vector, 4 mg of the reporter vector containing luciferase and 20 mg of the eector vector (expression constructs of TFE3, PRCC and derived translocation products) as described above. Cells were allowed to grow for 2 days after electroporation before harvesting. After two washes with PBS, cells were harvested by scraping, washed with PBS, collected by centrifugation, and resuspended in lysis buer (25 mM Bicine pH 7.8, 0.05% Tween 20, and 0.05% Tween 80). Lysis was allowed to proceed for 20 min at room temperature. Lysates were centrifuged for 15 min at 48C at 19 000 g. The resulting supernatant was stored at 7808C until use. The amount of protein was determined using the Biorad protein assay (Biorad, Hercules, CA, USA), and bGAL assays were performed to correct for dierences in transformation eciency (Edlund et al., 1985) . Twenty-®ve or 50 mg of protein corrected for the bGAL values, was used to perform the luciferase assay according to the instructions of the manufacturer (Promega, Madison, WI, USA). Luciferase activity was measured in a luminometer (Lumat EG&G Berthold).
All assays were performed six times, using several independently isolated DNA batches of the eector plasmids.
Western blot analysis
The pellet fraction of the same lysates used for the reporter assays was boiled for 5 min in SDS-sample buer before loading aliquots onto SDS-polyacrylamide gels. Immunoblotting was performed according to the method of Towbin et al. (1979) using nitrocellulose membranes (Schleicher and Schuell, Germany). After blocking overnight in 5% non fat dry milk/Phosphate Buered Saline containing 0,05% Tween-20 (PBST) the blot was incubated with the primary antibody in a 1 : 500 dilution. The R4 polyclonal antibody against TFE3 was generously provided by Dr Calame. After washes with PBST the blot was subsequently incubated with a swine anti-rabbit coupled horse radish peroxidase (DAKO, Denmark). Peroxidase activity was detected using a chemoluminescent reaction (ECL kit, Amersham, UK).
